Heather Raymon
Fortune : 1 M $ au 31/05/2026
Fortune : 1 M $ au 31/05/2026
Heather Raymon currently works at Artiva Biotherapeutics, Inc., as Senior VP-Research & Early Development from 2023.
Dr. Raymon also formerly worked at Bristol Myers Squibb Co., as Executive Director-Early Development Program and Celgene Corp., as Senior Director & Head-Pharmacology.
Dr. Raymon received her undergraduate degree from State University of New York at Albany and doctorate degree from the University of California, Irvine.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/05/2026 | 148 228 ( 0,31 % ) | 1 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2020 |
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
State University of New York at Albany
State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national